Epix makes progress in US with Vasovist trial
This article was originally published in Clinica
After numerous stumbling blocks, things are looking up for Epix as the US FDA has authorised a protocol for the re-analysis of trial results that is key to the approval of its Vasovist imaging agent. The company should now be firmly on the path to gaining approval by the end of 2008, company spokesperson Keri Mattox told Clinica.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.